Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Algernon Pharmaceuticals Inc (AGNPF)

Algernon Pharmaceuticals Inc (AGNPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0504 +25.99%
on 03/04/25
0.0700 -9.29%
on 02/21/25
-0.0008 (-1.24%)
since 02/19/25
3-Month
0.0400 +58.75%
on 12/30/24
0.0900 -29.44%
on 02/11/25
+0.0221 (+53.38%)
since 12/20/24
52-Week
0.0375 +69.33%
on 12/20/24
0.1230 -48.37%
on 05/22/24
-0.0083 (-11.56%)
since 03/20/24

Most Recent Stories

More News
Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing

AGN.CN : 0.0900 (unch)
AGNPF : 0.0635 (+11.40%)
Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study

AGN.CN : 0.0900 (unch)
AGNPF : 0.0635 (+11.40%)
Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity Investment

AGN.CN : 0.0900 (unch)
AGNPF : 0.0635 (+11.40%)
Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent

AGN.CN : 0.0900 (unch)
AGNPF : 0.0635 (+11.40%)
Algernon Announces Warrant Extension

AGN.CN : 0.0900 (unch)
AGNPF : 0.0635 (+11.40%)
Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference

VANCOUVER, British Columbia, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...

AGN.CN : 0.0900 (unch)
AGNPF : 0.0635 (+11.40%)
Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

VANCOUVER, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...

AGN.CN : 0.0900 (unch)
AGNPF : 0.0635 (+11.40%)
Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

VANCOUVER, British Columbia, July 07, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...

AGN.CN : 0.0900 (unch)
AGNPF : 0.0635 (+11.40%)
Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

VANCOUVER, British Columbia, July 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...

AGN.CN : 0.0900 (unch)
AGNPF : 0.0635 (+11.40%)
Algernon Pharmaceuticals Announces Closing of Public Offering of Units

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 04, 2022 (GLOBE NEWSWIRE) --...

AGN.CN : 0.0900 (unch)
AGNPF : 0.0635 (+11.40%)

Key Turning Points

3rd Resistance Point 0.0635
2nd Resistance Point 0.0635
1st Resistance Point 0.0635
Last Price 0.0635
1st Support Level 0.0635
2nd Support Level 0.0635
3rd Support Level 0.0635

See More

52-Week High 0.1230
Fibonacci 61.8% 0.0903
Fibonacci 50% 0.0803
Fibonacci 38.2% 0.0702
Last Price 0.0635
52-Week Low 0.0375

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar